Cargando…

Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition

Oral administration of tumour cells induces an immune hypo-responsiveness known as oral tolerance. We have previously shown that oral tolerance to a cancer is tumour antigen specific, non-cross-reactive and confers a tumour growth advantage. We investigated the utilisation of regulatory T cell (Treg...

Descripción completa

Detalles Bibliográficos
Autores principales: Whelan, Maria C., Casey, Garrett, Larkin, John O., Guinn, Barbara-ann, O'Sullivan, Gerald C., Tangney, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022586/
https://www.ncbi.nlm.nih.gov/pubmed/24832130
http://dx.doi.org/10.1371/journal.pone.0097602
_version_ 1782316433540120576
author Whelan, Maria C.
Casey, Garrett
Larkin, John O.
Guinn, Barbara-ann
O'Sullivan, Gerald C.
Tangney, Mark
author_facet Whelan, Maria C.
Casey, Garrett
Larkin, John O.
Guinn, Barbara-ann
O'Sullivan, Gerald C.
Tangney, Mark
author_sort Whelan, Maria C.
collection PubMed
description Oral administration of tumour cells induces an immune hypo-responsiveness known as oral tolerance. We have previously shown that oral tolerance to a cancer is tumour antigen specific, non-cross-reactive and confers a tumour growth advantage. We investigated the utilisation of regulatory T cell (Treg) depletion on oral tolerance to a cancer and its ability to control tumour growth. Balb/C mice were gavage fed homogenised tumour tissue – JBS fibrosarcoma (to induce oral tolerance to a cancer), or PBS as control. Growth of subcutaneous JBS tumours were measured; splenic tissue excised and flow cytometry used to quantify and compare systemic Tregs and T effector (Teff) cell populations. Prior to and/or following tumour feeding, mice were intraperitoneally administered anti-CD25, to inactivate systemic Tregs, or given isotype antibody as a control. Mice which were orally tolerised prior to subcutaneous tumour induction, displayed significantly higher systemic Treg levels (14% vs 6%) and faster tumour growth rates than controls (p<0.05). Complete regression of tumours were only seen after Treg inactivation and occurred in all groups - this was not inhibited by tumour feeding. The cure rates for Treg inactivation were 60% during tolerisation, 75% during tumour growth and 100% during inactivation for both tolerisation and tumour growth. Depletion of Tregs gave rise to an increased number of Teff cells. Treg depletion post-tolerisation and post-tumour induction led to the complete regression of all tumours on tumour bearing mice. Oral administration of tumour tissue, confers a tumour growth advantage and is accompanied by an increase in systemic Treg levels. The administration of anti-CD25 Ab decreased Treg numbers and caused an increase in Teffs. Most notably Treg cell inhibition overcame established oral tolerance with consequent tumor regression, especially relevant to foregut cancers where oral tolerance is likely to be induced by the shedding of tumour tissue into the gut.
format Online
Article
Text
id pubmed-4022586
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40225862014-05-21 Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition Whelan, Maria C. Casey, Garrett Larkin, John O. Guinn, Barbara-ann O'Sullivan, Gerald C. Tangney, Mark PLoS One Research Article Oral administration of tumour cells induces an immune hypo-responsiveness known as oral tolerance. We have previously shown that oral tolerance to a cancer is tumour antigen specific, non-cross-reactive and confers a tumour growth advantage. We investigated the utilisation of regulatory T cell (Treg) depletion on oral tolerance to a cancer and its ability to control tumour growth. Balb/C mice were gavage fed homogenised tumour tissue – JBS fibrosarcoma (to induce oral tolerance to a cancer), or PBS as control. Growth of subcutaneous JBS tumours were measured; splenic tissue excised and flow cytometry used to quantify and compare systemic Tregs and T effector (Teff) cell populations. Prior to and/or following tumour feeding, mice were intraperitoneally administered anti-CD25, to inactivate systemic Tregs, or given isotype antibody as a control. Mice which were orally tolerised prior to subcutaneous tumour induction, displayed significantly higher systemic Treg levels (14% vs 6%) and faster tumour growth rates than controls (p<0.05). Complete regression of tumours were only seen after Treg inactivation and occurred in all groups - this was not inhibited by tumour feeding. The cure rates for Treg inactivation were 60% during tolerisation, 75% during tumour growth and 100% during inactivation for both tolerisation and tumour growth. Depletion of Tregs gave rise to an increased number of Teff cells. Treg depletion post-tolerisation and post-tumour induction led to the complete regression of all tumours on tumour bearing mice. Oral administration of tumour tissue, confers a tumour growth advantage and is accompanied by an increase in systemic Treg levels. The administration of anti-CD25 Ab decreased Treg numbers and caused an increase in Teffs. Most notably Treg cell inhibition overcame established oral tolerance with consequent tumor regression, especially relevant to foregut cancers where oral tolerance is likely to be induced by the shedding of tumour tissue into the gut. Public Library of Science 2014-05-15 /pmc/articles/PMC4022586/ /pubmed/24832130 http://dx.doi.org/10.1371/journal.pone.0097602 Text en © 2014 Whelan et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Whelan, Maria C.
Casey, Garrett
Larkin, John O.
Guinn, Barbara-ann
O'Sullivan, Gerald C.
Tangney, Mark
Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition
title Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition
title_full Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition
title_fullStr Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition
title_full_unstemmed Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition
title_short Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition
title_sort oral tolerance to cancer can be abrogated by t regulatory cell inhibition
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022586/
https://www.ncbi.nlm.nih.gov/pubmed/24832130
http://dx.doi.org/10.1371/journal.pone.0097602
work_keys_str_mv AT whelanmariac oraltolerancetocancercanbeabrogatedbytregulatorycellinhibition
AT caseygarrett oraltolerancetocancercanbeabrogatedbytregulatorycellinhibition
AT larkinjohno oraltolerancetocancercanbeabrogatedbytregulatorycellinhibition
AT guinnbarbaraann oraltolerancetocancercanbeabrogatedbytregulatorycellinhibition
AT osullivangeraldc oraltolerancetocancercanbeabrogatedbytregulatorycellinhibition
AT tangneymark oraltolerancetocancercanbeabrogatedbytregulatorycellinhibition